Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Assets (2016 - 2025)

Historic Assets for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $218.4 million.

  • Altimmune's Assets rose 4773.51% to $218.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.4 million, marking a year-over-year increase of 4773.51%. This contributed to the annual value of $139.3 million for FY2024, which is 3386.54% down from last year.
  • Per Altimmune's latest filing, its Assets stood at $218.4 million for Q3 2025, which was up 4773.51% from $190.4 million recorded in Q2 2025.
  • Altimmune's 5-year Assets high stood at $264.3 million for Q1 2021, and its period low was $139.3 million during Q4 2024.
  • Over the past 5 years, Altimmune's median Assets value was $205.7 million (recorded in 2022), while the average stood at $199.3 million.
  • Per our database at Business Quant, Altimmune's Assets skyrocketed by 38724.97% in 2021 and then tumbled by 3386.54% in 2024.
  • Altimmune's Assets (Quarter) stood at $218.9 million in 2021, then dropped by 5.45% to $206.9 million in 2022, then grew by 1.79% to $210.6 million in 2023, then plummeted by 33.87% to $139.3 million in 2024, then soared by 56.81% to $218.4 million in 2025.
  • Its Assets was $218.4 million in Q3 2025, compared to $190.4 million in Q2 2025 and $157.3 million in Q1 2025.